Your browser is no longer supported. Please, upgrade your browser.
Settings
OPXA Opexa Therapeutics, Inc. daily Stock Chart
OPXA [NASD]
Opexa Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.88 Insider Own0.40% Shs Outstand6.87M Perf Week-7.96%
Market Cap12.71M Forward P/E- EPS next Y-3.19 Insider Trans0.00% Shs Float6.66M Perf Month-4.15%
Income-13.00M PEG- EPS next Q-0.50 Inst Own11.60% Short Float4.06% Perf Quarter-44.94%
Sales2.10M P/S6.05 EPS this Y56.70% Inst Trans0.63% Short Ratio1.28 Perf Half Y-40.71%
Book/sh1.70 P/B1.09 EPS next Y-71.50% ROA-87.60% Target Price12.80 Perf Year-68.75%
Cash/sh2.27 P/C0.81 EPS next 5Y- ROE-146.40% 52W Range1.69 - 8.64 Perf YTD-33.20%
Dividend- P/FCF- EPS past 5Y-3.50% ROI-202.70% 52W High-78.59% Beta1.46
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low9.47% ATR0.16
Employees39 Current Ratio3.20 Sales Q/Q133.30% Oper. Margin- RSI (14)38.75 Volatility7.18% 8.65%
OptionableNo Debt/Eq0.00 EPS Q/Q62.20% Profit Margin- Rel Volume0.07 Prev Close1.72
ShortableYes LT Debt/Eq0.00 EarningsFeb 23 AMC Payout- Avg Volume211.87K Price1.85
Recom2.00 SMA20-3.29% SMA50-25.82% SMA200-42.27% Volume15,833 Change7.56%
Nov-04-15Initiated Chardan Capital Markets Buy
Sep-28-15Reiterated Maxim Group Buy $5 → $18
May-27-15Initiated Maxim Group Buy $5
May-30-14Initiated Aegis Capital Buy $4
Mar-30-10Initiated Rodman & Renshaw Mkt Outperform $6
Feb-20-07Initiated MDB Capital Group Buy $8
Jan-29-16 02:24PM  Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference at noodls
Jan-28-16 09:00AM  Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference Marketwired
Dec-08-15 01:17PM  OPEXA THERAPEUTICS, INC. Financials
11:33AM  Opexa Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Nov-24-15 04:31PM  Logic Has Nothing to Do With This Market +12.17%
01:20PM  Computer Games Play the Market
11:18AM  4 Stocks to Watch That are Trading Up Today on Heavy Volume Accesswire
10:39AM  And Here Are the Dip Buyers
Nov-17-15 08:00AM  Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch Business Wire
Nov-10-15 04:11PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
04:06PM  OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
04:05PM  Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) Program Business Wire
04:01PM  Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q3 2015 Opexa Therapeutics Inc Earnings Release - After Market Close
Nov-06-15 08:30AM  Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results Business Wire
Nov-04-15 08:41AM  Chardan Starts Opexa Therapeutics With Buy Rating, $6 Price Target +14.85%
Oct-20-15 07:30PM  Edited Transcript of OPXA earnings conference call or presentation 12-Aug-15 9:00pm GMT -5.15%
Oct-19-15 08:11AM  Opexa Therapeutics to Host Analyst and Investor Event on November 10 in New York Business Wire
Oct-15-15 08:59AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.23%
08:00AM  Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement Business Wire
Oct-13-15 07:00AM  Opexa Therapeutics to Present at BIO Investor Forum Business Wire
Oct-08-15 09:15AM  SeeThruEquity Issues Update on Opexa Therapeutics, Inc. (NASDAQ: OPXA) Highlighting New Patents and Reverse Stock Split Accesswire
Oct-06-15 07:00AM  Opexa Announces Granting of New T-cell Patents Covering Tcelna®; Patent Estate Increases to 160 Issued Patents Business Wire +9.48%
Oct-01-15 10:26AM  Opexa Therapeutics, Inc. Earnings Q2, 2015
Sep-29-15 07:03AM  Splits Calendar: Opexa Therapeutics splits before market open today (1:8 ratio) -15.63%
Sep-28-15 07:03AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Artic -21.74%
07:00AM  Opexa Announces Reverse Stock Split Business Wire
Sep-10-15 09:15AM  SeeThruEquity Issues Update on Opexa Therapeutics, Inc. (NASDAQ: OPXA) Highlighting NMO Program Accesswire
Sep-03-15 04:31PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Sep-02-15 10:10AM  Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc. Marketwired
06:05AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-01-15 07:11AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity +7.14%
06:00AM  Opexa Secures Private Funding for its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study Business Wire
Aug-28-15 09:00AM  Opexa Therapeutics to Present at September Conferences Business Wire
Aug-27-15 09:00AM  SeeThruEquity Initiates Coverage on Opexa Therapeutics, Inc. (NASDAQ: OPXA) with a Price Target of $3.06 Accesswire +15.15%
Aug-14-15 08:10PM  10-Q for Opexa Therapeutics, Inc. at Company Spotlight
Aug-12-15 04:08PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:02PM  Opexa Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q2 2015 Opexa Therapeutics Inc Earnings Release - After Market Close
Aug-03-15 07:00AM  Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2015 Financial Results Business Wire -5.00%
Jun-11-15 08:00AM  Opexa Therapeutics CEO to Present at BIO 2015 International Convention Business Wire
Jun-09-15 08:00AM  Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development Business Wire
Jun-04-15 04:16PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
Jun-02-15 04:44PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St +14.00%
May-27-15 05:41AM  Coverage initiated on Opexa Therapeutics by Maxim Group +33.33%
May-21-15 08:00AM  Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference Business Wire
May-14-15 08:11PM  10-Q for Opexa Therapeutics, Inc. at Company Spotlight -7.14%
May-13-15 08:00AM  Opexa Therapeutics CEO Invited to Participate in Multiple May Conferences Business Wire +10.53%
May-12-15 04:06PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
04:01PM  Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update Business Wire
07:07AM  Q1 2015 Opexa Therapeutics Inc Earnings Release - After Market Close
May-11-15 08:00AM  Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2015 Financial Results Business Wire
Apr-20-15 08:15AM  Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology (AAN) 2015 Annual Meeting at noodls
08:00AM  Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology (AAN) 2015 Annual Meeting Business Wire
Apr-09-15 07:06AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:04AM  Opexa Therapeutics, Inc. Announces Completion of Rights Offering at noodls
07:00AM  Opexa Therapeutics, Inc. Announces Completion of Rights Offering Business Wire
Apr-06-15 08:03AM  Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2015 at 5:00 PM ET at noodls
08:00AM  Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2015 at 5:00 PM ET Business Wire
Apr-01-15 06:14AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events -7.27%
Mar-18-15 04:31AM  Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2015 at 4:00 PM ET at noodls
Mar-10-15 05:16PM  Merck KGaA to Pay $3M to Opexa for Tcelna Study - Analyst Blog +7.89%
09:24AM  Opexa Therapeutics Reports Year End 2014 Financial Results and Provides Corporate Update at noodls
09:00AM  Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2015 at 4:00 PM ET Business Wire
Mar-09-15 07:13AM  Opexa Therapeutics, Inc. Announces Record Date and Subscription Price for Rights Offering at noodls -6.17%
07:13AM  Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis at noodls
07:02AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh
07:00AM  Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis Business Wire
Feb-25-15 07:08PM  10-K for Opexa Therapeutics, Inc. at Company Spotlight +5.63%
05:22PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
05:10PM  Opexa Therapeutics, Inc. Announces Record Date and Subscription Price for Rights Offering Business Wire
Feb-23-15 06:11AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online -5.48%
06:05AM  Opexa Therapeutics Reports Year End 2014 Financial Results and Provides Corporate Update Business Wire
06:04AM  OPEXA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Jan-28-15 06:13AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -6.41%
06:05AM  Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering Business Wire
Dec-16-14 03:52PM  Dave Gentry Features Top 5 Healthcare Stocks for 2015 on This Week's RedChip Money Report on Fox Business and Bloomberg GlobeNewswire
Dec-11-14 10:35AM  Small Cap Profiles: OPXA, NEWC, TRNS, MLER Accesswire
Dec-09-14 05:16PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St EDGAR Online
Nov-18-14 09:00AM  Opexa Therapeutics Selected as One of the Top 10 Advanced Therapy Projects to Watch Business Wire
Nov-11-14 09:00AM  Opexa Therapeutics CEO Invited to Join Personalized Medicine Panel at New York CEO Conference Business Wire
Nov-08-14 07:07PM  10-Q for Opexa Therapeutics, Inc. Company Spotlight
Nov-06-14 04:03PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online +5.75%
04:01PM  Opexa Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update Business Wire
Nov-05-14 09:00AM  Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Third Quarter 2014 Financial Results Business Wire -7.45%
Oct-22-14 09:00AM  Opexa Therapeutics Supports National Multiple Sclerosis Society and Walk MS Business Wire +6.12%
Oct-20-14 09:00AM  Opexa Therapeutics to Present at Cleveland Clinics 12th Annual Medical Innovation Summit Business Wire
Oct-09-14 07:00AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Oct-06-14 11:15AM  RedChip Announces Presentation Schedule for Its October 15-16 Online Investor Conference GlobeNewswire
Oct-02-14 02:09PM  Opexa Therapeutics Announces Analyst and Investor Event Business Wire
Sep-29-14 09:01AM  Opexa Strengthens Patent Portfolio with Expansion Into B-cell Diseases and Announces Allowance of 98th T-cell Patent Business Wire
Sep-16-14 08:36AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -12.60%
08:30AM  Opexa Therapeutics, Inc. Announces Termination of Public Offering of Common Stock Business Wire
Sep-15-14 04:25PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -5.22%
04:21PM  Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Business Wire
Sep-11-14 04:45PM  Momenta Gains on Purchase of Autoimmune Antibodies Zacks
Sep-08-14 07:30AM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:29AM  Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica (NMO) as next Development Program Business Wire
Sep-02-14 09:00AM  Opexa Therapeutics to Present at September Conferences Business Wire
Aug-14-14 04:23PM  OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology. The company's product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas.